Physician

Jeremiah N. Bivins, MD

According to 2025 Medicare claims, Jeremiah Bivins, MD (NPI: 1831355833) practices allergy/immunology in the Warner Robins, GA market, with the plurality of this provider's patient population coming from Houston, GA. This provider's primary affiliated billing organization is ALLERGY ASSOCIATES, PA (NPI: 1518242601; TIN: 620863368) and primary practice location at 31204-2028.

Bivins' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 529 traditional Medicare patients, billed 50,410 HCPCS/CPT codes, and received $837,377 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,713 prescription claims across 356 beneficiaries totaling $1,655,976 in drug costs, led by Orladeyo (Berotralstat Hydrochloride). DME data shows 121 claims. Open Payments data shows 80 records totaling $1,762. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $228,903 to $837,377. Similarly, Part D prescription costs have risen steadily, from $95,187 to $1,655,976. In contrast, DME billing represents a smaller volume and rose steadily, from $489 to $1,872.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	239	23,480	$228,903
2016	293	24,971	$232,137
2017	297	25,691	$267,366
2018	338	25,256	$265,426
2019	377	26,849	$361,908
2020	387	28,225	$378,285
2021	384	29,703	$399,820
2022	388	32,571	$517,540
2023	536	41,498	$645,488
2024	529	50,410	$837,377

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	165	696	$95,187
2016	189	861	$220,696
2017	176	775	$218,177
2018	205	819	$326,168
2019	202	913	$912,808
2020	188	944	$1,207,922
2021	218	980	$1,178,143
2022	239	1,118	$1,479,962
2023	297	1,299	$1,605,149
2024	356	1,713	$1,655,976

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	24	$28,405
2017	N/R	N/R	N/R
2018	N/R	62	$67,181
2019	N/R	63	$62,727
2020	N/R	130	$83,214
2021	N/R	154	$104,741
2022	N/R	127	$102,456
2023	N/R	147	$110,458
2024	N/R	121	$123,061

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	141	162	$58
95165	Professional service for preparation and provision of 1 or more antigens	164	7,810	$10
95117	Professional service for multiple injections of allergen	267	2,514	$8
95024	Test for allergy using allergenic extract injected into skin	89	1,401	$5
95004	Test for allergy using allergenic extract	99	7,282	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Orladeyo	Berotralstat Hydrochloride	13	364	$574,992
Fasenra	Benralizumab	44	2,274	$239,961
Dupixent Syringe	Dupilumab	59	1,652	$220,172
Xolair	Omalizumab	57	1,519	$153,539
Tezspire	Tezepelumab-Ekko	34	952	$134,382

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	13	$116,382
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	24	$3,663
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	25	$1,373
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	33	$854
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	13	$564

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	80	$1,762	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeremiah N. Bivins, MD?

Tedicare shows public-source Medicare data for Jeremiah N. Bivins, MD (NPI 1831355833), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeremiah N. Bivins, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jeremiah N. Bivins, MD?

Jeremiah N. Bivins, MD is linked to ALLERGY ASSOCIATES, PA (billing NPI 1518242601) in the available physician profile data.

Does Jeremiah N. Bivins, MD have Open Payments data?

Jeremiah N. Bivins, MD has 80 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.